Comparative efficacy of octreotide and somatostatin in acute pancreatitis: a controlled trial of inflammatory markers and hospital length of stay.

Eficacia comparada de octreótido y somatostatina en pancreatitis aguda: ensayo controlado sobre marcadores inflamatorios y duración de la estancia hospitalaria.

• Qunchao Zhu Department of Emergency Medicine, The First People’s Hospital of Jiashan, Jiashan Hospital Affiliated of Jiaxing University, Jiashan, Zhejiang Province, China. https://orcid.org/0009-0004-6987-6091
• Tian Jiang Department of Thoracic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi Province, China. https://orcid.org/0009-0002-5083-5500
• Yan Li Department of Endocrinology, Jiujiang Hukou County People’s Hospital, Hukou, Jiangxi Province, China. https://orcid.org/0009-0002-4819-7941
• Sicong Jiang Department of Emergency Medicine, The First People’s Hospital of Jiashan, Jiashan Hospital Affiliated of Jiaxing University, Jiashan, Zhejiang Province, China. https://orcid.org/0000-0001-8974-6770
• Aifang Li Department of Hematology, Jiamusi University Affiliated First Hospital, Jiamusi, Heilongjiang Province, China. https://orcid.org/0009-0008-7880-6078
• Chendong Ma Department of Emergency Medicine, The First People’s Hospital of Jiashan, Jiashan Hospital Affiliated of Jiaxing University, Jiashan, Zhejiang Province, China. https://orcid.org/0009-0003-3787-5468

DOI: https://doi.org/10.54817/IC.v67n2a03

Palabras clave: Pancreatitis Aguda, Octreótido, Somatostatina, Inflamación, Hospitalización

Resumen

La pancreatitis aguda es una lesión pancreática de etiología múltiple. El octreótido y la somatostatina son tratamientos habituales para esta condición, aunque su eficacia clínica sigue siendo controvertida. Este estudio compara sus efectos sobre los índices inflamatorios y el tiempo de hospitalización. Se incluyeron retrospectivamente 120 pacientes con pancreatitis aguda ingresados en el First People’s Hospital of Jiashan entre enero de 2022 y diciembre de 2024, distribuidos en dos grupos según el tratamiento recibido: grupo control (tratamiento con somatostatina) y grupo experimental (tratamiento con octreótido), con 60 casos en cada grupo. Se evaluaron en ambos grupos la amilasa sérica (AMY), lipasa sérica (LPS), proteína C reactiva (PCR), interleucina-6 (IL -6), factor de necrosis tumoral α (TNF-α), recuento de leucocitos (WBC), albúmina sérica (ALB), procalcitonina (PCT), duración de la estancia hospitalaria e incidencia de reacciones adversas. Los datos basa- les de ambos grupos no mostraron diferencias estadísticamente significativas, lo que confirma su comparabilidad (p>0,05). Después de 7 días de medicación, en comparación con el grupo control, los pacientes del grupo experi- mental presentaron niveles más bajos de AMY, LPS, PCR, IL -6, TNF-α, WBC y PCT (p<0,05); la duración de la estancia hospitalaria fue menor (p=0,011); y la incidencia de reacciones adversas fue inferior (p=0,007). Los niveles de ALB en el grupo experimental fueron significativamente más altos que en el grupo control (p=0,039). En comparación con la somatostatina, el octreótido muestra una eficacia terapéutica superior en la pancreatitis aguda, aliviando la inflamación de forma más marcada, favoreciendo la recuperación, mejorando la eficacia clínica y acortando la hospitalización. Estos resultados aportan una base científica para optimizar el tratamiento farmacológico clínico.

Citas

Mederos MA, Reber HA, Girgis MD. Acute Pancreatitis: A Review. JAMA. 2021; 325 (4): 382-90. https://doi.org/10.1001/jama.2020.20317.

Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J. Chronic pancreatitis. Lancet. 2020; 396 (10249): 499-512. https://doi.org/10.1016/S0140-6736(20)31318-0.

Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020; 20(5): 795-800. https://doi.org/10.1016/j.pan.2020.06.005.

Saini J, Marino D, Badalov N, Vugelman M, Tenner S. Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised). Clin Transl Gastroenterol. 2023; 14(8): e00621. https://doi.org/10.14309/etg.0000000000000621.

Sohail Z, Shaikh II, Iqbal N, Parkash O. Acute pancreatitis: A narrative review. J Pak Med Assoc. 2024; 74(5): 953-8. https://doi.org/10.47391/JPMA.9280.

Gardner TB. Acute Pancreatitis. Ann Intern Med. 2021; 174(2): ITC17-ITC32. https://doi.org/10.7326/AITC202102160.

Horváth IL, Bunduc S, Fehérvári P, Vánesa S, Nagy R, Garmaa G, et al. The combination of ulinastatin and somatostatin reduces complication rates in acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2022; 12(1): 17979. https://doi.org/10.1038/s41598-022-22341-7.

He C, Liu J, Xu L, Sun F. The Effect of Percutaneous Catheter Drainage Combined with Somatostatin on Inflammation and Plasma Thromboxane 2, Prostacyclin I2 Levels in Patients with Severe Pancreatitis. Georgian Med News. 2024: 352/353 (7/8) 278-283.

Ampofo E, Nalbach L, Menger MD, Laschke MW. Regulatory Mechanisms of Somatostatin Expression. Int J Mol Sci. 2020; 21(11):4170. https://doi.org/10.3390/ijms21114170.

Khedr A, Mahmoud EE, Attallah N, Mir M, Boike S, Rauf I, et al. Role of octreotide in small bowel bleeding. World J Clin Cases. 2022; 10(26): 9192-9206. https://doi.org/10.12998/wjce.v10.126.9192.

Huang ZY, Gong H, Tang CW, Wang MJ, Wang R. Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostatin, octreotide and cyclooxygenase-2 inhibitors. Pancreatology. 2024; 24(1): 24-31. https://doi.org/10.1016/j.pan.2023.12.006.

Chinese Pancreatic Surgery Association CSOSCMA. Guidelines for diagnosis and treatment of acute pancreatitis in China (2021). Zhonghua Wai Ke Za Zhi. 2021; 59: 578-587. https://doi.org/10.3760/cma.j.cn112139-20210416-00172.

Cao JP, Piao XH, Zhu LX, Feng PF. Xuebijing and somatostatin against acute pancreatitis: A systematic review and network pharmacology. Medicine (Baltimore). 2024; 103(50): e40964. https://doi.org/10.1097/MD.0000000000040964.

Sliwinska-Mosson M. Marek G, Grzebieniak Z, Milnerowicz H. Relationship between somatostatin and interleukin-6: A cross-sectional study in patients with acute pancreatitis. Pancreatology. 2018; 18(8): 885-891.https://doi.org/10.1016/j.pan.2018.09.013.

Bao W, Kong R, Wang N, Han W, Lu J. PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis. PPAR Res. 2021; 2021: 6629455. https://doi.org/10.1155/2021/6629455.

Zheng XL, Li WL, Lin YP, Huang TL. Computerized tomography-guided therapeutic percutaneous puncture catheter drainage-combined with somatostatin for severe acute pancreatitis: An analysis of efficacy and safety. World J Gastrointest Surg. 2024; 16(1): 59-66. https://doi.org/10.4240/wjgs.v16.11.59.

Rivera-Suazo Y, Vázquez-Frias R. Factors associated with hospital length of stay in children with acute pancreatitis. Rev Gastroenterol Mex. (Engl Ed). 2023; 88(1): 4-11. https://doi.org/10.1016/j.rgmxen.2021.05.016.

Zhu LX, Chen Y, Chen XF, Sheng N, Feng PF. Systematic Review and Meta-analysis of the Clinical Efficacy of Octreotide in Combination with Ulinastatin in the Treatment of Acute Pancreatitis. Drugs R D. 2025; 25(3): 195-207. https://doi.org/10.1007/s40268-025-00518-5.

Chen ZP, Huang HP, He XY, Wu BZ, Liu Y. Early continuous blood purification affects TNF-alpha, IL-1beta, and IL-6 in patients with severe acute pancreatitis via inhibiting TLR4 signaling pathway. Kaohsiung J Med Sci. 2022; 38(5): 479-485. https://doi.org/10.1002/kjm2.12497.

Zerem E, Kurtcehajic A, Kunosić S, Zerem Malkočević D, Zerem O. Current trends in acute pancreatitis: Diagnostic and therapeutic challenges. World J Gastroenterol. 2023: 29(18): 2747-2763. https://doi.org/10.3748/wjg.v29.i18.2747.

Hong W, Pan J, Goyal H, Zippi M. Acute pancreatitis infection: Epidemiology, prevention, clinical characteristics, treatment, and prediction. Front Cell Infect Microbiol. 2023; 13: 1175195. https://doi.org/10.3389/fcimb.2023.1175195.

Niu JW, Zhang GC, Ning W, Liu HB, Yang H, Li CF. Clinical effects of phospholipase D2 in attenuating acute pancreatitis. World J Gastroenterol. 2025; 31(2): 97239. https://doi.org/10.3748/wjg.v31.i12.97239.

Wang L, Qi X, Tian F, Li H, Zhao H, Lv J, et al. Diagnostic value of hematological parameters in acute pancreatitis. Ann Palliat Med. 2020; 9(5): 2716-2722. https://doi.org/10.21037/apm-20-160. Epub 2020 Jul 23. PMID: 32787347.

Sun C, Li Z, Shi Z, Li G. Current diagnosis and treatment of acute pancreatitis in China: a real-world, multicenter study. BMC Gastroenterol. 2021; 21(1): 210. https://doi.org/10.1186/s12876-021-01799-1.

Potempa M, Hart PC, Rajab IM, Potempa LA. Redefining CRP in tissue injury and repair: more than an acute pro-inflammatory mediator. Front Immunol. 2025; 16: 1564607. https://doi.org/10.3389/fimmu.2025.1564607.

Ashrafizadeh M. Cell Death Mechanisms in Human Cancers: Molecular Pathways, Therapy Resistance and Therapeutic Perspective. J Can Biomol Therap. 2024; 1(1): 17-40. https://doi.org/10.62382/jebt.v1i1.13.


Velissaris D, Zareifopoulos N, Lagadinou M, Platanaki C, Tsiotsios K, Stavridis EL, et al. Procalcitonin and sepsis in the Emergency Department: an update. Eur Rev Med Pharmacol Sci. 2021; 25(1): 466-479. https://doi.org/10.26355/eurrev_202101_24416.

Mao X, Yang Z. Current usage status of somatostatin and its analogs and trypsin inhibitors: a real-world study of 34,654 Chinese adult patients with acute pancreatitis. Ann Palliat Med. 2021; 10(2): 1325-1335. https://doi.org/10.21037/apm-19-363.

Ullah A, Shin G, Lim SI. Human serum albumin binders: A piggyback ride for long-acting therapeutics. Drug Discov Today. 2023; 28(10): 103738. https://doi.org/10.1016/j.drudis.2023.103738.

Bhansali SK, Shah SC, Desai SB, Sunawala JD. Infected necrosis complicating acute pancreatitis: experience with 131 cases. Indian J Gastroenterol. 2003; 22(1): 7-10. PMID: 12617444.

Li ZF, Xu MY, Zhang DH, Gao TT, Gao Z, Li H. Effects of ulinastatin combined with octreotide on blood coagulation function, inflammatory factors and amylase in patients with severe acute pancreatitis. J Biol Regulators Homeostatic Agents. 2020; 34(6): 2147-2151. https://doi.org/10.23812/20-362-L.

Chen F, Xu Y, Wang Z. Ulinastatin combined with somatostatin enhances disease control and modulates serum inflammatory factors in patients with severe pancreatitis. Am J Transl Res. 2023; 15(9): 5797-5807. PMID: 37854214.

Dou H, Kan Y, Xu Z, Wang Z, Zheng C. Effect of probiotics combined with Ulinastatin and Somatostatin in the treatment of severe acute pancreatitis. Pak J Med Sci. 2024; 40(8): 1729-1734. https://doi.org/10.12669/pjms.40.8.9744.

Rykina-Tameeva N, Samra JS, Sahni S, Mittal A. Non-Surgical Interventions for the Prevention of Clinically Relevant Postoperative Pancreatic Fistula-A Narrative Review. Cancers (Basel). 2023; 15(24):5865. https://doi.org/10.3390/cancers15245865.

Nickel F, Anthony Wise P. Acute pancreatitis and multiple organ failure-Who beats the odds? United European Gastroenterol J. 2021; 9(2): 137-138. https://doi.org/10.1002/ueg2.12056.